Who Paid My Doc
Ray Wyman
Interventional Cardiology Torrance, CA Medical Doctor
NPI 1316956857 CMS profile 14700
2841 Lomita Blvd, Ste. 100, Torrance, CA 90505
General payments
$176,507
Research payments
$0
Ownership & investment interest
$149,997
Research they led as principal investigator
$62,842
Through program year 2025, Ray Wyman of Torrance, CA is reported in the CMS Open Payments database as having received $176,507 across 325 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $62,842 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $149,997 across 3 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,198 | 54 | |
| 2024 | General | $12,880 | 53 | |
| 2023 | General | $19,048 | 30 | |
| 2022 | General | $24,968 | 55 | |
| 2021 | General | $16,702 | 26 | |
| 2020 | General | $31,456 | 24 | |
| 2019 | General | $67,255 | 83 | |
| 2025 | Ownership | $49,999 | 1 | |
| 2024 | Ownership | $49,999 | 1 | |
| 2023 | Ownership | $50,000 | 1 |
Beside peers
- Ray Wyman
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Ray Wyman were reported at $4,198. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Ray Wyman | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $67,255 | $1,097 | $329–$3,048 | $163 |
| 2020 | $31,456 | $473 | $161–$1,480 | $114 |
| 2021 | $16,702 | $677 | $233–$1,827 | $132 |
| 2022 | $24,968 | $978 | $333–$2,724 | $149 |
| 2023 | $19,048 | $1,136 | $382–$2,986 | $160 |
| 2024 | $12,880 | $1,181 | $395–$3,326 | $164 |
| 2025 | $4,198 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 34 drugsPart D claims
3,227
Drug cost
$712,804
Branded share of claims
35.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 180 | $229,377 | |
| Entresto Sacubitril/Valsartan | Brand | 126 | $171,842 | |
| Repatha Sureclick Evolocumab | Brand | 104 | $89,356 | |
| Xarelto Rivaroxaban | Brand | 62 | $84,372 | |
| Brilinta Ticagrelor | Brand | 45 | $42,143 | |
| Farxiga Dapagliflozin Propanediol | Brand | 26 | $28,886 | |
| Praluent Pen Alirocumab | Brand | 33 | $20,911 | |
| Vascepa Icosapent Ethyl | Brand | 24 | $11,400 | |
| Atorvastatin Calcium | Generic | 542 | $6,016 | |
| Ezetimibe | Generic | 211 | $5,293 |
The 10 drugs with the highest cost, of 34 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 61 billing codesPaid by Medicare
$118,867
Medicare patients
733
Services billed
1,626
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 60% | |
| Arthritis | 47% | |
| Diabetes | 46% | |
| Chronic kidney disease | 39% | |
| Heart failure | 37% | |
| Atrial fibrillation | 36% | |
| Depression | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
325 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in California
Matthew Price
Interventional Cardiology · La Jolla, CA
Frederick St Goar
Interventional Cardiology · Mountain View, CA
Saibal Kar
Interventional Cardiology · Thousand Oaks, CA
Rahul Sharma
Interventional Cardiology · Stanford, CA
Puneet Khanna
Interventional Cardiology · Rancho Mirage, CA
Dennis Sheehan
Interventional Cardiology · Redwood City, CA
Related records
Interventional Cardiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.